7th Annual Atlanta Lung Cancer Symposium

7th Annual Atlanta
Lung Cancer Symposium

AUDIO/VIDEO PRESENTATIONS Participants must view activity in its entirety to receive full credit for this program.
	Click Here to View the Full Activity
	New International Lung Adenocarcinoma Classification William D. Travis, MD
	Emerging Lung Cancer Sub-Types: EML4-ALK Mutant; KRAS Mutant in Non-Smokers Alice T. Shaw, MD, PhD
	Revision of Lung Cancer TNM Classification Harvey I. Pass, MD
	Q & A Session for the three presentations above
	Beyond First-Line Therapy in NSCLC: Timing and Choices Edward S. Kim, MD
	Peri-Operative Therapy for Early NSCLC: Different Approaches for Smokers and Non-Smokers? Mark G. Kris, MD
	Role of Surgery in Stage III NSCLC Robert J. Cerfolio, MD, FACS, FCCP
	Genomics and Early Stage NSCLC Robert J. Cerfolio, MD, FACS, FCCP
	Smoking Cessation and the Lung Cancer Epidemic in the 20th Century: Interim Report Card Michael J. Thun, MD, MS
	Markers to Predict Response to Chemotherapy in Advanced NSCLC Rodolfo E. Bordoni, MD
	Integrating Molecular Markers and Targeted Therapies in Advanced NSCLC Suresh S. Ramalingam, MD
	Novel Agents in Development for Lung Cancer Fadlo R. Khuri, MD
	Combined Modality in the Management of Locally Advanced NSCLC: Blending Chemotherapy, Radiation, and Targeted Therapy Walter J. Curran Jr, MD
	Maintenance Therapy in the Advanced NSCLC: Definitions and Indications Chandra P. Belani, MD

DOWNLOAD SLIDE PRESENTATIONS
	New International Lung Adenocarcinoma Classification William D. Travis, MD
	Emerging Lung Cancer Sub-Types: EML4-ALK Mutant; KRAS Mutant in Non-Smokers Alice T. Shaw, MD, PhD
	Revision of Lung Cancer TNM Classification Harvey I. Pass, MD
	Beyond First-Line Therapy in NSCLC: Timing and Choices Edward S. Kim, MD
	Peri-Operative Therapy for Early NSCLC: Different Approaches for Smokers and Non-Smokers? Mark G. Kris, MD
	Role of Surgery in Stage III NSCLC Robert J. Cerfolio, MD, FACS, FCCP
	Genomics and Early Stage NSCLC Robert J. Cerfolio, MD, FACS, FCCP
	Smoking Cessation and the Lung Cancer Epidemic in the 20th Century: Interim Report Card Michael J. Thun, MD, MS
	Markers to Predict Response to Chemotherapy in Advanced NSCLC Rodolfo E. Bordoni, MD
	Integrating Molecular Markers and Targeted Therapies in Advanced NSCLC Suresh S. Ramalingam, MD
	Novel Agents in Development for Lung Cancer Fadlo R. Khuri, MD
	Combined Modality in the Management of Locally Advanced NSCLC: Blending Chemotherapy, Radiation, and Targeted Therapy Walter J. Curran Jr, MD
	Maintenance Therapy in the Advanced NSCLC: Definitions and Indications Chandra P. Belani, MD

CHAIRS

Rodolfo E. Bordoni, MD
Chairman, Research and Therapeutics
Georgia Cancer Specialists
Chairman, Department of Medicine
WellStar Kennestone Hospital
Atlanta, Georgia

Fadlo R. Khuri, MD
Roberto C. Goizueta Distinguished Professor and Chair
Department of Hematology and Medical Oncology
Deputy Director for Clinical and Translational Research
Emory University
Winship Cancer Institute
Atlanta, Georgia

FACULTY

Chandra P. Belani, MD

Robert J. Cerfolio, MD, FACS, FCCP

Walter J. Curran Jr, MD

Edward S. Kim, MD

Mark G. Kris, MD

Harvey I. Pass, MD

Suresh S. Ramalingam, MD

Alice T. Shaw, MD, PhD

Michael J. Thun, MD, MS

William D. Travis, MD

This activity is sponsored by

In association with

This activity is supported by educational grants from
Covidien, Genentech BioOncology & OSI Oncology, and Lilly USA, LLC

CLAIM CREDIT
	Click Here for Post-Test

DOWNLOAD PROGRAM AGENDA
Click Here for Agenda

QUESTIONS?
Jackie Falconer
jfalconer@educationalconcepts.net
1.770.933.1696

Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, GA 30339